Current Perspectives in Haematological Malignancies
Bristol

DoubleTree by Hilton, Bristol City Centre, Redcliffe Way, Bristol BS1 6NJ

PROGRAMME TOPICS:

CLL
Relapsed CLL: Have the new therapies completely replaced chemotherapy?

AML
Evolution in the management of AML

ALL
MRD and blinatumomab
MRD relevance pre and post-transplant

Workshop in Myeloma
Upfront treatments
Relapse in myeloma
Patient-based discussion

MDS
New treatments and iron chelation

Lymphoma MDT – Carousel of Cases Chair:
– Managing high risk DLBCL – is there anything better than RCHOP
– Combined modality treatment in early Hodgkin lymphoma
– Refractory late Hodgkin lymphoma
– Managing FL that’s behaving badly

Confirmed Speakers:
· Professor Graham Jackson, NCCC Newcastle
· Dr Ceri Bygrave University Hospital of Wales, Cardiff
· Dr Hannah Hunter University Hospitals Plymouth
· Professor Chris Fegan University Hospital of Wales
· Professor David Marks University Hospitals Bristol
· Dr Steve Knapper University Hospital of Wales
· Dr Jonathan Kell University Hospital of Wales
· Dr Andrew McMillan Nottingham University Hospitals
· Dr Steve Robinson University Hospitals Bristol
· Professor Tim Illidge Christie Hospital Manchester
· Dr Wendy Osborne NCCC Newcastle

Registration Fees:

(inclusive of VAT @ 20%)

Consultants

Trainees / Nurses*

Standard Fee (until 7th November)

£72

£60

Late Fee (from 8th November)

£108

£108

* 20 free places available for Trainees & Nurses(allocated on a first-come, first-served basis – please email This email address is being protected from spambots. You need JavaScript enabled to view it. to check availability)

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator

calculator

Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here